MARKET

ELTX

ELTX

Elicio Therapeutics, Inc.
NASDAQ
1.900
-0.040
-2.06%
After Hours: 1.900 0 0.00% 19:30 10/23 EDT
OPEN
1.940
PREV CLOSE
1.940
HIGH
1.980
LOW
1.790
VOLUME
464.09K
TURNOVER
--
52 WEEK HIGH
16.00
52 WEEK LOW
1.440
MARKET CAP
51.47M
P/E (TTM)
-0.8724
1D
5D
1M
3M
1Y
5Y
1D
Elicio Therapeutics reports AMPLIFY-7P study misses primary endpoint
TipRanks · 18h ago
Elicio Therapeutics Presents Late-Breaking Phase 2 AMPLIFY-7P Results At ESMO Congress 2026; Multiple Pre-Specified Subgroup Analyses Favored Camupepimut, Including Patients With And Without Detectable Baseline ctDNA; Encouraging Disease-Free Survival Outcomes Were Observed In Both ctDNA-Negative And ctDNA-Positive Patients
Benzinga · 18h ago
Elicio Therapeutics Presents Data From Its Phase 2 AMPLIFY-7P Trial Of Camupepimut At European Society For Medical Oncology Congress 2026
Benzinga · 18h ago
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 1d ago
Weekly Report: what happened at ELTX last week (1012-1016)?
Weekly Report · 4d ago
Weekly Report: what happened at ELTX last week (1005-1009)?
Weekly Report · 10/12 09:54
Weekly Report: what happened at ELTX last week (0928-1002)?
Weekly Report · 10/05 09:53
Weekly Report: what happened at ELTX last week (0921-0925)?
Weekly Report · 09/28 09:50
More
About ELTX
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.

Webull offers Elicio Therapeutics Inc stock information, including NASDAQ: ELTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ELTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ELTX stock methods without spending real money on the virtual paper trading platform.